Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | PTAFR | P25105 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737986 | 0.83 | MMP13 (0.49) | MMP1MMP13 | |
| SCHEMBL6730246 | 0.81 | HDAC1 (0.46) | EPHX2MMP13 | |
| SCHEMBL6735747 | 0.81 | CHRNB2 (0.42) | EPHX2CHRNB2CHRNA4KDM4EKMT2A | |
| SCHEMBL6732607 | 0.73 | CYP4F2 (0.44) | CYP4F2CYP4A11 | |
| SCHEMBL28749443 | 0.72 | ALDH1A1 (0.47) | KMT2AMMP1MMP13CYP4F2CYP4A11 | |
| SCHEMBL6968315 | 0.71 | CYP4F2 (0.45) | EPHX2CHRNB2CHRNA4KMT2AMMP1 | |
| SCHEMBL10672431 | 0.70 | CHRNB2 (0.48) | CHRNB2CHRNA4KMT2A | |
| SCHEMBL6731754 | 0.68 | USP2 (0.47) | EPHX2KDM4EKMT2AMMP1MMP13 | |
| SCHEMBL14235509 | 0.68 | MMP1 (0.41) | MMP1MMP13 | |
| SCHEMBL7077468 | 0.66 | CHRNB2 (0.46) | CHRNB2CHRNA4KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | MONTANA JOHN GARY (GB) | 2004-07-01 | — | — | US | claimed |
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2003-12-25 | — | — | US | claimed |
| EP-1053233-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2000-11-22 | — | — | EP | claimed |
| WO-1999040080-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 1999-08-12 | — | — | WO | claimed |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | MONTANA JOHN GARY (GB) | 2004-07-01 | — | — | US | disclosed |
| US-6680338-B2 | MATRIX METALLOPROTEINASE AND TUMOR NECROSIS FACTOR INHIBITORS; ANTICARCINOGENIC AGENTS; RHEUMATOID ARTHRITIS | DARWIN DISCOVERY LTD. (GB) | 2004-01-20 | — | — | US | disclosed |
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-1053233-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-08-20 | — | — | EP | disclosed |
| EP-1053233-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999040080-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | HCAR1, HCAR2, HCAR3 | EPHX2 875/4885CHRNB2 1125/4885CHRNA4 997/4885 |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, CBR1 | EPHX2 923/4885CHRNB2 1034/4885CHRNA4 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.